Mediators of Inflammation / 2022 / Article / Tab 1 / Review Article
Effect of Statins on Serum level of hs-CRP and CRP in Patients with Cardiovascular Diseases: A Systematic Review and Meta-Analysis of Randomized Controlled Trials Table 1 Demographic characteristics of the included studies.
Study author Year Country Intervention/control (sample size) Intervention (M Mean age (intervention/control) Intervention duration (week) Target population Dosage (mg/day) Dosage category Hydrophilic or lipophilic Jadad scale Intervention name Hs-CRP Luo et al. 2004 China 11/9 3 AMI 20 M Lipophile 2 Simvastatin Luo et al. 2004 China 14/16 3 Unstable angina 20 M Lipophile 2 Simvastatin Azar et al. 2005 Lebanon 44/26 NR 1 CAD NR — — 3 Statins Marschang et al. 2006 Austria 47/16 24 CAD NR — — 3 Statins Sola et al. 2006 USA 54/54 96 Heart failure 20 M Lipophile 4 Atorvastatin Yang et al. (i) 2006 China 20/20 1 ACS 40 L Lipophile 3 Fluvastatin Yang et al. (ii) 2006 China 20/20 1 ACS 80 M Lipophile 3 Fluvastatin Chan et al. (i) 2008 Taiwan 30/30 12 CAD 10 M Lipophile 3 Atorvastatin Chan et al. (ii) 2008 Taiwan 30/30 24 CAD 10 M Lipophile 3 Atorvastatin Suzuki et al. (i) 2008 Japan 10/9 NR 12 CAD 10 L Lipophile 4 Fluvastatin Suzuki et al. (ii) 2008 Japan 10/9 NR 12 CAD 10 L Hydrophile 4 Pravastatin Vasilieva et al. 2008 Russia 19/20 NR 1 ACS 40 H Lipophile 3 Atorvastatin McMurray et al. (i) 2009 UK 777/779 12 Heart failure 10 M Hydrophile 4 Rosuvastatin hs-CRP 2.0 mg/L McMurray et al. (ii) 2009 UK 1711/1694 12 Heart failure 10 M Hydrophile 4 Rosuvastatin hs-CRP 2.0 mg/L Yun et al. 2009 Korea 225/220 1 ACS 40 H Hydrophile 2 Rosuvastatin Andreou et al. 2010 Greece 21/18 4 Heart failure 10 M Hydrophile 3 Rosuvastatin Dohi et al. 2010 Japan 85/84 24 ACS 20 M Lipophile 3 Atorvastatin Yun et al. 2011 Korea 237/242 1 ACS NR — — 3 Statins Abulhul et al. 2012 Ireland 28/28 24 Heart failure 40 H Lipophile 3 Atorvastatin Guo et al. (i) 2012 China 47/54 24 Stable atherosclerotic plaque 10 M Lipophile 3 Atorvastatin Guo et al. (ii) 2012 China 45/54 24 Stable atherosclerotic plaque 20 M Lipophile 3 Atorvastatin Guo et al. (iii) 2012 China 43/54 24 Stable atherosclerotic plaque 40 H Lipophile 3 Atorvastatin Guo et al. (iiii) 2012 China 39/54 24 Stable atherosclerotic plaque 80 H Lipophile 3 Atorvastatin Jiao et al. (i) 2015 China 62/64 1 ACS 20 H Hydrophile 2 Rosuvastatin Jiao et al. (ii) 2015 China 62/64 4 ACS 20 H Hydrophile 2 Rosuvastatin Qiao et al. 2019 China 82/78 2 Carotid artery stenting 40 H Lipophile 3 Atorvastatin CRP Correia et al. 2003 Brazil 18/18 1 ACS 80 H Lipophile 3 Atorvastatin Karaca et al. 2003 Turkey 46/32 NR 52/52 4 CAD 20 M Lipophile 3 Atorvastatin Kinlay et al. (i) 2003 USA 1186/1216 16 ACS 80 H Lipophile 3 Atorvastatin Kinlay et al. (ii) 2003 USA 555/544 NR NR/NR 16 Unstable angina 80 H Lipophile 3 Atorvastatin Kinlay et al.(iii) 2003 USA 631/672 NR NR/NR 16 MI 80 H Lipophile 3 Atorvastatin Ostadal et al. 2003 Czech Republic 13/17 NR/NR 1 MI 0/3 — 2 Cerivastatin Macin et al. 2004 Argentina 44/46 4 ACS 40 H Lipophile 3 Atorvastatin Doo et al. (i) 2005 China 20/30 1 Unstable angina NR — 2 Statins Doo et al. (ii) 2005 China 20/30 1 Unstable angina NR — 2 Statins Li et al. 2005 China 19/17 NR NR/NR 4 Unstable angina 20 M Lipophile 3 Atorvastatin Link et al. (i) 2006 Germany 18/17 NR 55.5/60 1 ACS 20 H Hydrophile 3 Rosuvastatin Link et al. (ii) 2006 Germany 18/17 NR 55.5/60 1 ACS 20 H Hydrophile 3 Rosuvastatin Link et al. (iii) 2006 Germany 18/17 NR 55.5/60 6 ACS 20 H Hydrophile 3 Rosuvastatin Li et al. 2007 China 18/16 NR/NR 1 Unstable angina 20 M Lipophile 3 Simvastatin Patti et al. 2007 Italy 86/85 1 ACS 80 H Lipophile 3 Atorvastatin Lewandowski et al. (i) 2008 Poland 39/39 1 ACS 40 H Lipophile 3 Atorvastatin Lewandowski et al. (ii) 2008 Poland 39/39 6 ACS 40 H Lipophile 3 Atorvastatin Nakagomi et al. 2012 Japan 63/83 24 Heart failure NR — 2 Statins Gruzdeva et al. 2016 Russia 60/66 56.5/60.4 2 MI 20 M Lipophile 3 Atorvastatin Strazhesko et al. 2016 Italy 44/38 48 Atherosclerosis 20 M Lipophile 3 Atorvastatin
NR: not reported; MI: myocardial infraction; ACS: acute coronary syndrome; CAD: coronary artery disease; H: high; M: moderate; L: low; M
male; F: female.
